Prescient Therapeutics Shareholder Replay 8th June 2023

June 5, 2023

Prescient Therapeutics: Cell Therapies presentations from ISCT

Prescient Therapeutics held a special Cell Therapies briefing to discuss data presented at the prestigious International Society of Cell & Gene Therapy (ISCT) conference in Paris in June 2023.

CEO and MD of Prescient Therapeutics, Steven Yatomi-Clarke, Senior VP of Scientific Affairs at Prescient, Dr Rebecca Lim, and post-doctoral scientist at the Peter MacCallum Cancer Centre, Dr Kevin Sek, discussed:

  • Prescient’s next-gen modular, controllable CAR platform, OmniCAR.
  • Clinic-ready cell therapy enhancement platform, CellPryme.
  • How these cell therapy technologies overcome the limitations of existing and emerging cell therapies.

Recorded on 8th June 2023 at 12:00pm (AEST)

View the posters presented at ISCT

Join the next Prescient Therapeutics webcast

Register to stay up to date with Prescient Therapeutics

Featured Speakers

Steven Yatomi-Clarke

CEO and Managing Director

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.

Dr Rebecca Lim

Senior Vice President of Scientific Affairs at Prescient Therapeutics

Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.

Dr Kevin Sek

Postdoctoral Researcher at Peter MacCallum Cancer Centre

Dr Kevin Sek is a postdoctoral researcher at the Peter MacCallum Cancer Centre. He has conducted extensive research into enhancing CAR-T therapies and previously undertook postdoctoral research with Prescient Therapeutics.

Related Post

This investor centre was built by Reach Markets

©2022 Reach Markets

×

Do you qualify as a Wholesale (708) investor?

Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.
  • A gross income of $250,000 or more per annum in each of the previous two financial years; or
  • Net assets of at least $2.5 million; and
  • A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
×

Any advice is general only

Any advice provided by Reach Markets, the Lead Manager on this offer, including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice.

×

Receive email updates

What is a 708 investor?

By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.